uniQure Stock Forecast, Price & News

uniQure (NASDAQ:QURE) Frequently Asked Questions

Is uniQure a buy right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for uniQure in the last twelve months. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" uniQure stock.
View analyst ratings for uniQure or view top-rated stocks.

How has uniQure's stock been impacted by Coronavirus (COVID-19)?

uniQure's stock was trading at $47.54 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, QURE shares have decreased by 62.1% and is now trading at $18.03.
View which stocks have been most impacted by COVID-19.

Are investors shorting uniQure?

uniQure saw a increase in short interest in December. As of December 31st, there was short interest totaling 2,870,000 shares, an increase of 22.1% from the December 15th total of 2,350,000 shares. Based on an average daily trading volume, of 592,200 shares, the days-to-cover ratio is currently 4.8 days. Currently, 7.5% of the shares of the stock are sold short.
View uniQure's Short Interest.

When is uniQure's next earnings date?

uniQure is scheduled to release its next quarterly earnings announcement on Monday, March 7th 2022.
View our earnings forecast for uniQure.

How were uniQure's earnings last quarter?

uniQure (NASDAQ:QURE) announced its quarterly earnings results on Sunday, October, 24th. The biotechnology company reported ($0.79) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($1.05) by $0.26. The biotechnology company earned $2 million during the quarter, compared to analyst estimates of $2.13 million. uniQure had a trailing twelve-month return on equity of 75.59% and a net margin of 64.09%. The business's revenue for the quarter was up 11.1% on a year-over-year basis. During the same period last year, the company posted ($1.21) EPS.
View uniQure's earnings history.

What price target have analysts set for QURE?

10 analysts have issued 1 year price targets for uniQure's stock. Their forecasts range from $27.46 to $95.00. On average, they expect uniQure's share price to reach $59.31 in the next year. This suggests a possible upside of 228.9% from the stock's current price.
View analysts' price targets for uniQure or view top-rated stocks among Wall Street analysts.

Who are uniQure's key executives?

uniQure's management team includes the following people:

• Matt Kapusta, Chief Executive Officer & Executive Director
• Pierre Caloz, Chief Operating Officer
• Christian Klemt, Chief Financial Officer (LinkedIn Profile)
• Ricardo Dolmetsch, President-Research & Development (LinkedIn Profile)
• Maria E. Cantor, Chief Communications Officer

What is Matthew Kapusta's approval rating as uniQure's CEO?

8 employees have rated uniQure CEO Matthew Kapusta on Glassdoor.com. Matthew Kapusta has an approval rating of 74% among uniQure's employees.

Who are some of uniQure's key competitors?

Some companies that are related to uniQure include Karuna Therapeutics (KRTX), Apellis Pharmaceuticals (APLS), Dicerna Pharmaceuticals (DRNA), Prestige Consumer Healthcare (PBH), OPKO Health (OPK), Pacira BioSciences (PCRX), PTC Therapeutics (PTCT), Insmed (INSM), Cytokinetics (CYTK), Zentalis Pharmaceuticals (ZNTL), Emergent BioSolutions (EBS), Amicus Therapeutics (FOLD), Mawson Infrastructure Group (WIZP), Sage Therapeutics (SAGE) and I-Mab (IMAB).
View all of QURE's competitors.

What other stocks do shareholders of uniQure own?

Based on aggregate information from My MarketBeat watchlists, some companies that other uniQure investors own include Empire Resorts (NYNY), Micron Technology (MU), Gilead Sciences (GILD), Alibaba Group (BABA), AbbVie (ABBV), GW Pharmaceuticals (GWPH), NVIDIA (NVDA), Exelixis (EXEL), Square (SQ) and bluebird bio (BLUE).

What is uniQure's stock symbol?

uniQure trades on the NASDAQ under the ticker symbol "QURE."

Who are uniQure's major shareholders?

uniQure's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Nordea Investment Management AB (0.59%), Henry James International Management Inc. (0.34%), State of Alaska Department of Revenue (0.06%), Cutler Group LP (0.00%), Boenning & Scattergood Inc. (0.04%) and Future Financial Wealth Managment LLC (0.00%). Company insiders that own uniQure stock include Alexander Edward Kuta III, Christian Klemt, Deventer Sander Van, Jack Kaye, Matthew C Kapusta, Paula Soteropoulos, Philip Astley-Sparke, Ricardo Dolmetsch and Robert Gut.
View institutional ownership trends for uniQure.

Which major investors are selling uniQure stock?

QURE stock was sold by a variety of institutional investors in the last quarter, including Nordea Investment Management AB, and State of Alaska Department of Revenue. Company insiders that have sold uniQure company stock in the last year include Alexander Edward Kuta III, Christian Klemt, Matthew C Kapusta, Ricardo Dolmetsch, and Robert Gut.
View insider buying and selling activity for uniQure or view top insider-selling stocks.

Which major investors are buying uniQure stock?

QURE stock was bought by a variety of institutional investors in the last quarter, including Cutler Group LP, Boenning & Scattergood Inc., Future Financial Wealth Managment LLC, and Henry James International Management Inc..
View insider buying and selling activity for uniQure or or view top insider-buying stocks.

How do I buy shares of uniQure?

Shares of QURE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is uniQure's stock price today?

One share of QURE stock can currently be purchased for approximately $18.03.

How much money does uniQure make?

uniQure has a market capitalization of $833.24 million and generates $37.51 million in revenue each year. The biotechnology company earns $-125.02 million in net income (profit) each year or $6.80 on an earnings per share basis.

How many employees does uniQure have?

uniQure employs 332 workers across the globe.

What is uniQure's official website?

The official website for uniQure is www.uniqure.com.

Where are uniQure's headquarters?

uniQure is headquartered at PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP.

How can I contact uniQure?

uniQure's mailing address is PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP. The biotechnology company can be reached via phone at (120) 240-6000, via email at [email protected], or via fax at 31-20-566-9272.